22 September 2014
EMA/CHMP/465006/2014
Procedure Management and Business Support Division

Committee for medicinal products for human use (CHMP)

Agenda of meeting to be held on 22-25 September 2014

Chair: Tomas Salmonson – Vice-chair: Pierre Demolis

22 September 2014, 13:00 – 19:30, room 3A

23 September 2014, 08:30 – 19:30, room 3A

24 September 2014, 08:30 – 19:30, room 3A

25 September 2014, 08:30 – 16:00, room 3A

Note on access to documents

Some documents mentioned in the agenda/minutes cannot be released at present following a request for access to documents under Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Health & Safety Information

In accordance with the Agency's Health and Safety policy, delegates are to be briefed on health & safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential and therefore not disclosed. With regards to therapeutic indications listed against products it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. The procedures discussed by the CHMP are on-going and therefore are considered confidential. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. For orphan medicinal products the applicant details are published as this information is already publicly available. Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact

Further information with relevant explanatory notes can be found at the end of this document.

For adoption

Agenda (EMA/CHMP/465006/2014) and Annex to CHMP agenda of the CHMP plenary session to be held 22-25 September 2014	
Timeschedule (EMA/CHMP/564310/2014) of the CHMP plenary session to be held 22-25 September 2014	
Minutes (EMA/CHMP/471144/2014) of the CHMP plenary session held 21-24 July 2014	
Minutes (EMA/CHMP/433531/2014) of the September 2014 CHMP ORGAM meeting held on 15 September 2014	

For information

Membership Announcement	The Committee is asked to note that Maria Popova-Kiradjieva was nominated as the new Bulgarian CHMP alternate, replacing Lyubina Todorova in this role as of 30 July 2014. Furthermore Daniela Melchiorri and Luca Pani changed role. Prof Melchiorri is the new Italian member and Prof Pani the new Italian alternate as of 4 September 2014.
Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session to be held 22-25 September 2014.	*See September 2014 CHMP Minutes (to be published post October 2014 CHMP meeting)*
Draft Agenda of 20-23 October 2014 CHMP meeting	

Table of contents

1. Oral explanations

1.1. Pre-authorisation procedure oral explanations

(EMEA/H/C/003726), Orphan, (olaparib), Applicant: AstraZeneca AB, (treatment of ovarian cancer.) List of Outstanding Issues adopted on 26.06.2014. List of Questions adopted on 23.01.2014. • List of experts to SAG oncology held on 10 September 2014: **adopted by written procedure** • Report from SAG oncology meeting held on 10 September 2014: **For discussion**	Possible oral explanation to be held on Monday 22 September 2014 at 17.00.
(EMEA/H/C/002829), Orphan, (ramucirumab), Applicant: Eli Lilly Nederland B.V., (treatment of gastric cancer) List of Outstanding Issues adopted on 26.06.2014. List of Questions adopted on 23.01.2014.	Possible oral explanation to be held on Tuesday 23 September 2014 at 11.00.
(EMEA/H/C/002548), Orphan, (afamelanotide), Applicant: Clinuvel (UK) Limited, (treatment of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).) List of Outstanding Issues adopted on 23.01.2014, 21.03.2013. List of Questions adopted on 19.07.2012.	Oral explanation to be held on Tuesday 23 September 2014 at 14.00. Involvement of patient representatives.
(EMEA/H/C/003702), (phenylephrine hydrochloride / ketorolac trometamol), (maintenance of intraoperative mydriasis, prevention of intraoperative miosis and reduction of acute postoperative ocular pain in intraocular lens replacement (ILR) in adults) List of Outstanding Issues adopted on 22.05.2014. List of Questions adopted on 23.01.2014.	Oral explanation to be held on Wednesday 24 September 2014 at 9.00.

(EMEA/H/C/002314), (bazedoxifene / estrogens conjugated), (treatment of oestrogen deficiency) List of Outstanding Issues adopted in March, June 2014. List of Questions adopted in November 2012.	Opinion or possible oral explanation to be held on Wednesday 24 September 2014 at 11.00. See also 2.1. New applications- Opinions
(EMEA/H/C/002085), (tilmanocept), (used in the delineation and localisation of lymph nodes) List of Outstanding Issues adopted on 20.03.2014, 19.12.2013, 24.10.2013. List of Questions adopted on 30.05.2013. • Report from SAG oncology meeting held on 11 July 2014: **For discussion**	Opinion or possible oral explanation to be held on Wednesday 24 September 2014 at 14.00. See also 2.1 New applications- Opinions

1.2. Re-examination procedure oral explanation

Avastin (EMEA/H/C/000582/II/0059), (bevacizumab), MAH: Roche Registration Ltd, "Update of section 4.1 of the SmPC in order to extend the indication of Avastin in combination with radiotherapy and temozolomide for the treatment of adult patients with newly diagnosed glioblastoma." Opinion adopted on 22.05.2014.	Possible oral explanation to be held on Monday 22 September 2014 at 14.00. See also 7. Re-examination procedure (type II variations)

1.3. Post-authorisation procedure oral explanation

Javlor (EMEA/H/C/000983/II/0011), (vinflunine ditartrate), MAH: Pierre Fabre Médicament, Rapporteur: Greg Markey, Co-Rapporteur: Arantxa Sancho-Lopez, PRAC Rapporteur: Julie Williams, "extension of indication: in combination with capecitabine for the treatment of adult patients with locally advanced or metastatic breast cancer previously treated with or resistant to an anthracycline and who are taxane resistant." Request for Supplementary Information adopted on 25.04.2014, 19.09.2013. Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)	Possible oral explanation to be held on Tuesday 23 September 2014 at 9.00.

1.4. Referral procedures oral explanations

2. New applications

2.1. Opinions – New full applications

(EMEA/H/C/003969), (aclidinium / formoterol fumarate dihydrate), (maintenance bronchodilator treatment for airflow obstruction and relief of symptoms in adult patients with chronic obstructive pulmonary disease (COPD))
List of Outstanding Issues adopted on 24.07.2014.
List of Questions adopted on 20.03.2014.

(EMEA/H/C/003745), (aclidinium / formoterol fumarate dihydrate), (maintenance bronchodilator treatment for airflow obstruction and relief of symptoms in adult patients with chronic obstructive pulmonary disease (COPD))
List of Outstanding Issues adopted on 24.07.2014.
List of Questions adopted on 20.03.2014.

(EMEA/H/C/003951), (budesonide / formoterol), (treatment of asthma and treatment of patients with severe chronic obstructive pulmonary disease (COPD))
List of Questions adopted on 24.07.2014.

(EMEA/H/C/003952), (budesonide / formoterol), (treatment of asthma and treatment of patients with severe chronic obstructive pulmonary disease (COPD))
List of Questions adopted on 24.07.2014.

(EMEA/H/C/003953), (budesonide / formoterol), (treatment of asthma)
List of Questions adopted on 24.07.2014.

(EMEA/H/C/003724), Orphan, (eliglustat), Applicant: Genzyme Europe BV, (treatment of Gaucher disease type 1)
List of Outstanding Issues adopted on 24.07.2014.
List of Questions adopted on 20.02.2014.

(EMEA/H/C/004006), (clopidogrel), (prevention of myocardial infarction, ischaemic stroke, peripheral arterial disease, acute coronary syndrome, prevention of atherothrombotic and thromboembolic events in atrial fibrillation.)

(EMEA/H/C/002314), (bazedoxifene / estrogens conjugated), (treatment of oestrogen deficiency) List of Outstanding Issues adopted in March, June 2014. List of Questions adopted in November 2012.	Possible Opinion or Oral explanation See also 1.1 Pre-authorisation procedure oral explanations
(EMEA/H/C/002637), (balugrastim), (treatment of chemotherapy-induced neutropenia) List of Outstanding Issues adopted on 22.05.2014. List of Questions adopted on 19.09.2013.	
(EMEA/H/C/003850), (sofosbuvir / ledipasvir), (treatment of chronic hepatitis C) List of Questions adopted on 24.07.2014.	
(EMEA/H/C/003906), Orphan, (ketoconazole), Applicant: Laboratoire HRA Pharma (treatment of Cushing's syndrome) List of Questions adopted on 26.06.2014.	
(EMEA/H/C/002085), (tilmanocept), (used in the delineation and localisation of lymph nodes) List of Outstanding Issues adopted on 20.03.2014, 19.12.2013, 24.10.2013. List of Questions adopted on 30.05.2013. • Report from SAG oncology meeting held on 11 July 2014: **For discussion**	See also 1.1 Pre-authorisation procedure oral explanations
(EMEA/H/C/002810), (naloxegol), (indicated for the treatment of adult patients 18 years and older with opioid-induced constipation (OIC) including patients with inadequate response to laxatives.) List of Outstanding Issues adopted on 26.06.2014. List of Questions adopted on 23.01.2014.	
(EMEA/H/C/002819), (darunavir / cobicistat), (The treatment of patients with human immunodeficiency virus (HIV-1) in - antiretroviral therapy (ART) naïve adults. - ART-experienced adults with no darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ⩾ 100 cells x 106/l.) List of Outstanding Issues adopted on 26.06.2014. List of Questions adopted on 20.02.2014.	

(EMEA/H/C/003971), (sevelamer), (control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis)

(EMEA/H/C/003968), (sevelamer), (control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis)

(EMEA/H/C/003787), (tadalafil), (treatment of erectile dysfunction in adult males)
List of Questions adopted on 25.04.2014.

(EMEA/H/C/002825), (dulaglutide), (treatment of adults with type 2 diabetes mellitus)
List of Questions adopted on 20.02.2014.

(EMEA/H/C/002569), (nintedanib), (treatment of non-small cell lung cancer (NSCLC))
List of Outstanding Issues adopted on 24.07.2014.
List of Questions adopted on 20.02.2014.

2.2. Day 180 List of outstanding issues – New full applications

(EMEA/H/C/003729), (secukinumab), (treatment of plaque psoriasis)
List of Questions adopted on 20.03.2014.

(EMEA/H/C/003773), (cangrelor), (Percutaneous coronary intervention (PCI)
Hemaxiv is a P2Y12 platelet inhibitor indicated for the reduction of thrombotic cardiovascular events (including stent thrombosis) in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI).
During the pre-operative period when oral P2Y12 therapy is interrupted due to surgery ('Bridging') Hemaxiv is also indicated to maintain P2Y12 inhibition in adult patients with acute coronary syndromes or in patients with stents who are at increased risk for thrombotic events (such as stent thrombosis) when oral P2Y12 therapy is interrupted due to surgery ('Bridging'))
List of Questions adopted on 25.04.2014.

(EMEA/H/C/002066), (ciclosporin), (treatment of dry eye disease in adult patients with severe keratitis that does not improve despite treatment with tear substitutes)
List of Questions adopted on 25.04.2014.

(EMEA/H/C/002789), Orphan, (levofloxacin), Applicant: Aptalis Pharma SAS, (indicated for chronic pulmonary infections)
List of Questions adopted on 25.04.2014.

(EMEA/H/C/003746), (apremilast), (treatment of psoriatic arthritis, psoriasis)
List of Questions adopted on 25.04.2014.

(EMEA/H/C/003771), (nonacog gamma), (treatment of haemophilia B)
List of Outstanding Issues adopted on 24.07.2014.
List of Questions adopted on 20.03.2014.

(EMEA/H/C/002396), (safinamide), (treatment of Parkinson's disease (PD))
List of Questions adopted on 25.04.2014.

(EMEA/H/C/002840), (dalbavancin), (treatment of complicated skin and soft tissue infections (cSSTI)
List of Questions adopted on 25.04.2014.

(EMEA/H/C/002814), (vorapaxar), (indicated for the reduction of atherothrombotic events)
List of Questions adopted on 25.04.2014.

2.3. Day 120 List of Questions – New full applications

(EMEA/H/C/003837), (dasabuvir), (treatment of chronic hepatitis C)

(EMEA/H/C/003725), Orphan, (panobinostat), Applicant: Novartis Pharmaceuticals UK Limited, (treatment of patients with multiple myeloma)

(EMEA/H/C/003870), Orphan, (tasimelteon), Applicant: Vanda Pharmaceuticals Ltd., (treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in the totally blind)

(EMEA/H/C/002839), (sonidegib), (treatment of advanced basal cell carcinoma (BCC))

(EMEA/H/C/003821), Orphan, (nintedanib), Applicant: Boehringer Ingelheim International GmbH, (treatment of Idiopathic Pulmonary Fibrosis (IPF))

(EMEA/H/C/003834), Orphan, (idebenone), Applicant: Santhera Pharmaceuticals (Deutschland) GmbH, (treatment of Leber's Hereditary Optic Neuropathy (LHON))

(EMEA/H/C/003839), (ombitasvir / paritaprevir / ritonavir), (treatment of chronic hepatitis C)

(EMEA/H/C/002616), Orphan, (pitolisant hydrochloride), Applicant: Bioprojet Pharma, (treatment of narcolepsy)

2.4. Update on on-going new applications for Centralised Procedures

(EMEA/H/C/003759), (guanfacine), (treatment of ADHD)
List of Questions adopted on 24.07.2014.

- Letter from the applicant dated 29.08.2014 requesting an additional extension of clock stop: **For information**

(EMEA/H/C/003776), (ferric citrate coordination complex), (treatment of hyperphosphataemia

- Letter from the applicant requesting an additional extension of clock stop: **For information**

2.5. Products in the Decision Making Phase

3. Extension of Marketing Authorisation according to Annex I of Regulation 1234/2008

3.1. Extension of marketing authorisation according to Annex I of Regulation 1234/2008; Opinions

Signifor (EMEA/H/C/002052/X/0010), Orphan, (pasireotide), MAH: Novartis Europharm Ltd, Rapporteur: Kristina Dunder, Co-Rapporteur: Joseph Emmerich, PRAC Rapporteur: Qun-Ying Yue, "Line extension application for Signifor to add 20mg, 40mg and 60mg powder and solvent for suspension for injection in the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative, or who are inadequately controlled on treatment with other somatostatin analogues."
List of Outstanding Issues adopted on 26 July 2014. List of Questions adopted on 20.03.2014.

3.2. Extension of marketing authorisation according to Annex I of Regulation 1234/2008; Day 180 List of outstanding issues

3.3. Extension of marketing authorisation according to Annex I of Regulation 1234/2008; Day 120 List of Questions

Oprymea (EMEA/H/C/000941/X/0017), (pramipexole), MAH: Krka d.d. Novo mesto, Generic, Generic of Sifrol, Rapporteur: Jens Heisterberg, PRAC Rapporteur: Doris Stenver, "To add new strengths 2.62 mg and 3.15 mg prolonged-release tablets."

Optisulin (EMEA/H/C/000309/X/0079/G), (insulin glargine), MAH: Sanofi-aventis Deutschland GmbH, Duplicate of Lantus, Rapporteur: Pieter de Graeff, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Menno van der Elst, "To extend MA of Optisulin to register additional strength 300 U/ml, grouped with type IA variation to vary the invented name from Optisulin to Toujeo"

Somavert (EMEA/H/C/000409/X/0072), (pegvisomant), MAH: Pfizer Limited, Rapporteur: Pierre Demolis, PRAC Rapporteur: Arnaud Batz, "Addition of 25 mg and 30 mg powder and solvent for solution for injection."

3.4. Update on on-going Extension application according to Annex I of Regulation. 1234/2008

4. Type II variations - Extension of indication procedures

4.1. Opinions or Requests for Supplementary information - Type II variation; Extension of indication

Abraxane (EMEA/H/C/000778/II/0067), (paclitaxel), MAH: Celgene Europe Limited, Rapporteur: Pieter de Graeff, Co-Rapporteur: Ingunn Hagen Westgaard, PRAC Rapporteur: Sabine Straus, "Extension of Indication to add a new indication for Abraxane in combination with carboplatin for the first-line treatment of non-small cell lung cancer (NSCLC) in adult patients who are not candidates for potentially curative surgery and/or radiation therapy. Consequently the MAH proposes to update sections 4.1, 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmpC and to update the Package Leaflet accordingly.
An updated RMP version 14.0 has been provided as part of the application."

Aloxi (EMEA/H/C/000563/II/0038), (palonosetron), MAH: Helsinn Birex Pharmaceuticals Ltd., Rapporteur: Patrick Salmon, Co-Rapporteur: Arantxa Sancho-Lopez, PRAC Rapporteur: Almath Spooner, "Extension of the therapeutic indication for paediatric patients 1 month of age and older for the prevention of nausea and vomiting associated with moderately and highly emetogenic cancer chemotherapy for the IV formulation, based on the paediatric studies PALO-10-14 and PALO-10-20 and update of sections 5.1 and 5.2 of the Aloxi Oral formulation to reflect those studies. The MAH took the opportunity of this variation to update the Aloxi product information annexes in line with Version 9 of the QRD template."

Avastin (EMEA/H/C/000582/II/0072), (bevacizumab), MAH: Roche Registration Ltd, Rapporteur: Christian Schneider, Co-Rapporteur: Ingunn Hagen Westgaard, PRAC Rapporteur: Doris Stenver, "Extension of indication for the use of Avastin in combination with paclitaxel and cisplatin or paclitaxel and topotecan in patient with persistent, recurrent, or metastatic carcinoma of the cervix. Consequently, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC and the Package Leaflet are proposed to be updated."	
Eylea (EMEA/H/C/002392/II/0013), (aflibercept), MAH: Bayer Pharma AG, Rapporteur: Pierre Demolis, Co-Rapporteur: Robert James Hemmings, PRAC Rapporteur: Arnaud Batz, "Extension of indication for the treatment of macular oedema following branch retinal vein occlusion (BRVO)."	
Jakavi (EMEA/H/C/002464/II/0016), Orphan, (ruxolitinib), MAH: Novartis Europharm Ltd, Rapporteur: Filip Josephson, Co-Rapporteur: Robert James Hemmings, PRAC Rapporteur: Ulla Wändel Liminga, "Extension of Indication to add treatment of adult patients with polycythaemia vera resistant to or intolerant of hydroxyurea."	
Javlor (EMEA/H/C/000983/II/0011), (vinflunine ditartrate), MAH: Pierre Fabre Médicament, Rapporteur: Greg Markey, Co-Rapporteur: Arantxa Sancho-Lopez, PRAC Rapporteur: Julie Williams, "Extension of Indication: in combination with capecitabine for the treatment of adult patients with locally advanced or metastatic breast cancer previously treated with or resistant to an anthracycline and who are taxane resistant." Request for Supplementary Information adopted on 25.04.2014, 19.09.2013. Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)	See also 1.3 Post-authorisation oral explanations

Prezista (EMEA/H/C/000707/II/0063), (darunavir), MAH: Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Greg Markey, PRAC Rapporteur: Sabine Straus, "Update of section 4.1 of the SmPC for the 100mg/ml oral suspension and the 400mg, 800mg film-coated tablets with information on the use of darunavir with cobicistat as pharmacokinetic enhancer."
Request for Supplementary Information adopted on 26.06.2014, 25.04.2014.

Prezista (EMEA/H/C/000707/II/0064), (darunavir), MAH: Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Greg Markey, PRAC Rapporteur: Sabine Straus, "Extension of indication in treatment of naïve children aged 3 to 12 years and changes in the posology of the treatment experienced children aged 3 to 12 years with no DRV RAMs based on the data from a 2 week qd substudy of the Phase 2 study TMC114 C228 and results from model-based pharmacokinetic simulations.
Request for Supplementary Information adopted on 22.05.2014.

Travatan (EMEA/H/C/000390/II/0046), (travoprost), MAH: Alcon Laboratories (UK) Ltd, Rapporteur: Concepcion Prieto Yerro, Co-Rapporteur: Greg Markey, PRAC Rapporteur: Dolores Montero Corominas, "Extension of the therapeutic indication for decrease of elevated intraocular pressure in paediatric patients with ocular hypertension or paediatric glaucoma."

Tresiba (EMEA/H/C/002498/II/0011), (insulin degludec), MAH: Novo Nordisk A/S, Rapporteur: Kristina Dunder, PRAC Rapporteur: Qun-Ying Yue, "Extension of the indication in children aged from 1 to 18 years."

Velcade (EMEA/H/C/000539/II/0072), (bortezomib), MAH: Janssen-Cilag International N.V., Rapporteur: Daniela Melchiorri, Co-Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Carmela Macchiarulo, "Extension of indication for the use of Velcade in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma."

Xagrid (EMEA/H/C/000480/II/0059), Orphan, (anagrelide), MAH: Shire Pharmaceutical Contracts Ltd., Rapporteur: Pierre Demolis, Co-Rapporteur: Daniel Brasseur, "Extension of indication for use in paediatric patients aged 6 to 17 years."
Request for Supplementary Information adopted on 24.07.2014, 22.05.2014.

Xiapex (EMEA/H/C/002048/II/0044), (collagenase clostridium histolyticum), MAH: Swedish Orphan Biovitrum AB (publ), Rapporteur: Martina Weise, Co-Rapporteur: Pierre Demolis, PRAC Rapporteur: Martin Huber, "Extension of the indication in the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity. The PL is updated accordingly."
Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

4.2. Update on on-going Type II variation - Extension of indications

5. Ancillary medicinal substances in medical devices

5.1. Opinions / List of outstanding issues / List of Questions

(EMEA/H/D/002769), (thrombin), (indicated in surgical procedures)
List of Outstanding Issues adopted on 26.06.2014, 25.04.2014.
List of Questions adopted on 19.09.2013.

- Opinion: **For adoption**

Floseal Hemostatic Matrix (Floseal VH S/D) (EMEA/H/D/000956/X/0016), (human thrombin), Applicant: TÜV SÜD Product Service GmbH, Rapporteur: Jan Mueller-Berghaus, "Addition of a new strength/concentration: 5000 IU Thrombin/vial (500 IU Thrombin/mL)."
List of Questions adopted on 22.05.2014.

- Opinion: **For adoption**

(EMEA/H/D/003740), (human serum albumin), (to scavenge embryotoxic components generated during embryo development and to facilitate embryo and gamete manipulation in IVF media)
List of Questions adopted on 23.01.2014

- List of Outstanding Issues: **For adoption**

(EMEA/H/D/002831), ((substance to be reviewed) insulin-like growth factor-i (igf-i) segment), (hard-to-heal wounds, primarily venous leg ulcers)
List of Questions adopted on 23.01.2014.

- List of Outstanding Issues: **For adoption**

---

6. Re-examination procedure (new applications) under Article 9(2) of Regulation EC No 726/2004

7. Re-examination procedure (type II variations) under Article 6(9) of Commission Regulation EC No 1085/2003

Avastin (EMEA/H/C/000582/II/0059), (bevacizumab), MAH: Roche Registration Ltd, "Update of section 4.1 of the SmPC in order to extend the indication of Avastin in combination with radiotherapy and temozolomide for the treatment of adult patients with newly diagnosed glioblastoma."
Opinion adopted on 22.05.2014.

- Re-examination Opinion: **For adoption**

---

8. Withdrawal of application

9. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

10. Pre-submission issues

Some items in this section are considered commercially confidential or sensitive and therefore not disclosed.

11. Post-authorisation issues

Some items in this section are considered commercially confidential or sensitive and therefore not disclosed.

Valdoxan, Thymanax
(EMEA/H/C/000916/PSUV/0021,
EMEA/H/C/000915/PSUV/0023)
(Agomelatine), MAH: Servier (Ireland) Industries Ltd., Rapporteur: Karsten Bruins Slot, Co-Rapporteur: Filip Josephson

- PRAC Recommendation: **For discussion**
- Product information: **For adoption**
- DHPC letter: **For discussion**

M-M-RVAXPRO
(EMEA/H/C/000604/II/0063), (measles, mumps and rubella vaccine (live)), MAH: Sanofi Pasteur MSD SNC, Rapporteur: Jan Mueller-Berghaus, “Update of section 4.8 of the SmPC in order to include "Transverse myelitis".

12. Referral Procedures

12.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

MACI (EMEA/H/C/002522/A20/0004)
(Matrix Applied Characterised Autologous Cultured Chondrocytes), MAH: Aastrom Biosciences DK ApS, Rapporteur: Elaine French, Co-Rapporteur: Johannes H. Ovelgönne, CHMP Co-ordinators: Greg Markey, Johann Lodewijk Hillege, (repair of symptomatic cartilage defects of the knee), New active substance (Article 8(3) of Directive No 2001/83/EC)

- Start of procedure
- Letter from the European Commission dated 10 September 2014 notifying of a referral under Article 20: **For information**
- Opinion: **For adoption**

12.2. Requests for CHMP Opinion under Article 5(3) and 57 (1)p of Regulation (EC) No 726/2004

12.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

12.4. Disagreement between Member States on application for medicinal product (Potential serious risk to Public Health) –under Article 29(4) of Directive 2001/83/EC

12.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

EMLA Cream (EMEA/H/A-30/1388)

(lidocaine / prilocaine), Astra Zeneca group of companies and associated companies,
Rapporteur: Martina Weise, Co-Rapporteur: Greg Markey,
Harmonisation exercise for EMLA Cream. The review was triggered by Germany, due to the need of harmonisation of the Summary of Product Characteristics across Member States. List of Outstanding Issues adopted on 22.05.2014, 24.07.2014. List of Questions adopted in October 2013. Extension of Timetable adopted in November 2013.

- Opinion: **For adoption**

Nasonex (EMEA/H/A-30/1374)

(mometasone), nasal spray suspension, MAH: Merck Sharp & Dohme, Rapporteur: Kristina Dunder, Co-Rapporteur: David Lyons,
Nasonex was included in the list of products for SmPC harmonisation, drawn up by the CMDh, in accordance with Article 30(2) of Directive 2001/83/EC.

- List of outstanding issues or Opinion: **For adoption**

Ikorel / Dancor and associated names (EMEA/H/A-30/1380)

(nicorandil), Sanofi-Aventis group of companies and associated companies / Merck group of companies and associated companies,
Rapporteur: Pierre Demolis, Co-Rapporteur: Pieter de Graeff,
Ikorel / Dancor was included in the list of products for SmPC harmonisation, drawn up by the CMDh, in accordance with Article 30(2) of Directive 2001/83/EC.

- List of outstanding issues: **For adoption**

Cymevene IV and associated names (EMEA/H/A-30/1406) (ganciclovir), F. Hoffmann-La Roche Rapporteur: Romaldas Maciulaitis, Co-Rapporteur: Alar Irs • Letter from the European Commission notifying of a referral under Article 30: **For information** • List of Questions: **For adoption** • Timetable: **For adoption**	Start of procedure

12.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

Adrenaline auto injectors (EMEA/H/A-31/1398) Rapporteur: Alars Irs, Co-Rapporteur: Robert Hemmings, Article 31 triggered by the MHRA due to the lack of robust evidence that the devices deliver the adrenaline intramuscularly in all patients. • List of outstanding issues: **For adoption**	
Gadolinium containing contrast agents, Gd-Cas (EMEA/H/A-31/1097) Rapporteur: Rafe Suvarna, Co-Rapporteur: Pieter de Graeff, • Assessment of the 4th annual cumulative review submissions: **For adoption**	
GVK Bio (EMEA/H/A-31/1408) Article 31 procedure triggered by the European Commission concerning GVK Biosciences Private Limited (GVK Bio), Swarna Jayanthi commercial complex, Ameerpet, Hyderabad 500 038, India • Letter from the European Commission dated 1 August 2014 informing of an official referral under Article 31 and its grounds: **For information** • List of Questions: **For adoption** • Timetable: **For adoption** • Appointment of (Co)Rapporteur: **For discussion**	Start of procedure

12.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

12.8. Procedure under Article 107(2) of Directive 2001/83/EC

Ketoprofen formulation for topical use (EMEA/H/A-107/1259)
(Ketum), Rapporteur: Joseph Emmerich, Co-Rapporteur: Radka Montoniová,
Assessment of MAHs' responses to the list of questions adopted in March 2014 concerning the Surveillance study of photo-contact dermatitis leading to hospitalisation in Europe with a special focus on topical ketoprofen and other topical NSAIDs, including evaluation of severe photosensitivity reactions (PASS pilot study) and the 3-years cumulative analysis of photosensitivity reactions including photo-allergy reactions together with a report of the effectiveness of risks minimisation measures

- CHMP Assessment Reports: **For adoption**

12.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) (EC) No 1084/2003)

12.10. Procedure under Article 29 Regulation (EC) 1901/2006

12.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) No 1234/2008)

13. Pharmacovigilance issues

Summary of recommendations and advice of PRAC meeting held on 8-11 September 2014: **For information**

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports

(EURD list) for September 2014: **For adoption**	
Early Notification System: September 2014 Early Notification System on Envisaged CHMP Recommendations for Regulatory Action (based on Identified Safety Concerns) Accompanied by Communication to the General Public: **for information**	
Options for assessment of experimental treatments for Ebola	

14. Inspections

14.1. GMP inspections

Request for GMP inspections: **For adoption**	*Disclosure of information related to GMP inspections will not be published as it undermines the purpose of such inspections.*

14.2. GCP Inspections

Request for GCP inspections: **For adoption**	*Disclosure of information related to GCP inspections will not be published as it undermines the purpose of such inspections.*

14.3. Pharmacovigilance inspections

Request for Pharmacovigilance inspections: **For adoption**	*Disclosure of information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections.*

14.4. GLP inspections

Request for GLP inspections: **For adoption**	*Disclosure of information related to GLP inspections will not be published as it undermines the purpose of such inspections.*

15. Innovation Task Force

15.1. Minutes of ITF: For information

15.2. Briefing meetings (Innovation Task Force)

Disclosure of information related to briefing meetings taking place with applicants cannot be released at present time as deemed to contain commercially confidential information.

15.3. Eligibility to EMA scientific services

15.4. Requests for CHMP Opinion under Article 57 (1)P of Regulation (EC) No 726/2004

Request from EDQM for EMA scientific Opinion under Art. 57 (1)P of Regulation (EC) No 726/2004 • Final Report: **For adoption**

15.5. Nanomedicines activities

16. Scientific Advice Working Party (SAWP)

Report from the SAWP meeting held on 1-4 September 2014 Table of conclusions: **For information**	
Scientific advice letters:	*Disclosure of information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.*

17. Satellite Groups

17.1. Coordination Group for Mutual Recognition and Decentralised Procedures

Report from the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) on the meeting held on 22-24 September 2014: **For information**
CMDh request for advice from QWP regarding the droplet size distribution for a nasal spray: **For discussion** Question on the clinical impact of differences in the Dv10 and Dv90 values of the droplet size distribution: **For information**

18. Other Committees

18.1. Committee for Orphan Medicinal Products (COMP)

Press release of the COMP meeting held on 3-4 September 2014: **For information**	To be sent in the Post-mail.

18.2. Committee for Herbal Medicinal Products (HMPC)

Not applicable.

18.3. Paediatric Committee (PDCO)

PIPs reaching D30 at September 2014 PDCO: **For information**	To be sent in the Post-mail.
Report from the PDCO meeting held on held on 10-12 September 2014: **For information**	

18.4. Committee for Advanced Therapies (CAT)

Table of Decisions of CAT meeting held on 18-19 September 2014: **For information**

19. Invented name issues

Table of Decisions of the NRG Table of Decisions of the NRG accelerated review procedure performed in August 2014: **For adoption**

20. Any other business

Area of expertise of Co-opted Member in light of Jan Mueller –Berghaus' mandate expiring in November 2014

Area of expertise: **For agreement**

CAT - expiry of mandates of CHMP representatives: **For discussion**

CHMP Work Plan 2015: **For information**

Procedural Advice on the CHMP/CAT/PRAC (Co)Rapporteur appointment: **For adoption**

Concept paper on the need for revision of the points to consider on the clinical investigation of new medicinal products for the treatment of acute coronary syndrome (CPMP/EWP/570/98 and

CPMP/EWP/967/01) (EMA/559636/2014): **For adoption and release for 3 months public consultation**
Request for nomination of Vice Chair for Central Nervous System Working Party The new vice-chair will be determined by the CHMP based on their expertise in neurology and psychiatry as well as experience within the European regulatory network in October 2014.
Q3D Guideline for Elemental Impurities: **For discussion**
Election of Vice-Chair of Pharmacogenomics Working Party
Election of Vice-Chair of Biostatistics Working Party
Nomination of new observer to the SAWP: **For endorsement**
Status update on proposed process improvements for initial MAA

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 1)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 2 and 3) or referral procedures (section 12) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

New applications *(section 2)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 2.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 2.2 (**Day 180 List of outstanding issues**) and 2.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 2.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 2.5, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 3)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 4)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 3. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 5)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of Regulation No 726/2004 *(section 6)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section 7)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 8)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of Regulation (EC) No 726/2004 (compassionate use) *(section 9)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 10)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 11)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 12)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 13)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 14)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 15)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 16)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 17)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 18)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.